NO20020687D0 - 3(5)-ureidopyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler - Google Patents

3(5)-ureidopyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler

Info

Publication number
NO20020687D0
NO20020687D0 NO20020687A NO20020687A NO20020687D0 NO 20020687 D0 NO20020687 D0 NO 20020687D0 NO 20020687 A NO20020687 A NO 20020687A NO 20020687 A NO20020687 A NO 20020687A NO 20020687 D0 NO20020687 D0 NO 20020687D0
Authority
NO
Norway
Prior art keywords
ureidopyrazole
derivatives
preparation
antitumor agents
antitumor
Prior art date
Application number
NO20020687A
Other languages
English (en)
Other versions
NO20020687L (no
Inventor
Paolo Pevarello
Paolo Orsini
Gabriella Traquandi
Mario Varasi
Edward L Fritzen
Martha A Warpehoski
Betsy S Pierce
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20020687D0 publication Critical patent/NO20020687D0/no
Publication of NO20020687L publication Critical patent/NO20020687L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20020687A 1999-08-12 2002-02-11 3(5)-ureido-pyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler NO20020687L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/372,833 US6387900B1 (en) 1999-08-12 1999-08-12 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
PCT/US2000/017878 WO2001012188A1 (en) 1999-08-12 2000-08-11 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents

Publications (2)

Publication Number Publication Date
NO20020687D0 true NO20020687D0 (no) 2002-02-11
NO20020687L NO20020687L (no) 2002-04-03

Family

ID=23469810

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020687A NO20020687L (no) 1999-08-12 2002-02-11 3(5)-ureido-pyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler

Country Status (25)

Country Link
US (1) US6387900B1 (no)
EP (1) EP1202734B1 (no)
JP (1) JP2003507328A (no)
KR (1) KR20020060158A (no)
CN (1) CN1379668A (no)
AR (1) AR035557A1 (no)
AT (1) ATE361070T1 (no)
AU (1) AU6747000A (no)
BR (1) BR0013277A (no)
CA (1) CA2380786A1 (no)
CO (1) CO5200848A1 (no)
DE (1) DE60034683T2 (no)
EA (1) EA200200249A1 (no)
ES (1) ES2284518T3 (no)
HK (1) HK1049790A1 (no)
HU (1) HUP0301857A2 (no)
IL (1) IL147925A0 (no)
MX (1) MXPA02001497A (no)
NO (1) NO20020687L (no)
NZ (1) NZ517238A (no)
PE (1) PE20010482A1 (no)
PL (1) PL354058A1 (no)
SK (1) SK2082002A3 (no)
WO (1) WO2001012188A1 (no)
ZA (1) ZA200201118B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL150388A0 (en) 1999-12-24 2002-12-01 Aventis Pharma Ltd Azaindoles
JP2003522174A (ja) * 2000-02-07 2003-07-22 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼの３−アミノピラゾール阻害剤
WO2001081348A1 (en) 2000-04-25 2001-11-01 Bristol-Myers Squibb Company USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
JP2004507526A (ja) * 2000-08-31 2004-03-11 ファイザー・プロダクツ・インク ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用
EP1345909A1 (en) * 2000-11-27 2003-09-24 Pharmacia Italia S.p.A. Phenylacetamido-pyrazole derivatives and their use as antitumor agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003047579A1 (en) * 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
KR20030071029A (ko) * 2002-02-27 2003-09-03 주식회사 팜제니아 항암제 및 방사선 치료 증진제로서 유용한 조성물
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
DE10221052A1 (de) * 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
CA2486101C (en) * 2002-05-17 2009-07-07 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
ATE548354T1 (de) 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
NZ538513A (en) * 2002-09-05 2007-02-23 Neurosearch As Diarylurea derivatives and their use as chloride channel blockers
WO2004033434A1 (en) * 2002-10-09 2004-04-22 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
GB0305426D0 (en) * 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
RS20050944A (en) 2003-05-22 2008-06-05 Nerviano Medical Sciences S.R.L., Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP4777887B2 (ja) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
EP1609789A1 (en) * 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
DK1778686T3 (da) * 2004-08-12 2009-01-12 Pfizer Triazolopyridinylsulfanylderivater som P38 MAP kinase-inhibitorer
DK2937341T3 (en) 2004-12-30 2017-09-11 Janssen Pharmaceutica Nv 4- (BENZYL) -PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID HYDROLASE (FAAH) FOR TREATING ANALYSIS, PAIN AND OTHER CONDITIONS
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
US7429800B2 (en) * 2005-06-30 2008-09-30 Sabic Innovative Plastics Ip B.V. Molding composition and method, and molded article
WO2007009898A1 (en) 2005-07-19 2007-01-25 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
CN101484438A (zh) * 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 吡唑衍生物及其作为p13k抑制剂的用途
RU2009119181A (ru) 2006-10-21 2010-11-27 Эбботт Гмбх Унд Ко.Кг (De) Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP5675343B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としての尿素誘導体
US20090062294A1 (en) * 2007-05-25 2009-03-05 Richard Apodaca Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
CN102231983A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
US8901111B2 (en) 2009-06-05 2014-12-02 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
JP2013531801A (ja) * 2010-07-02 2013-08-08 ヴェンタナ メディカル システムズ， インク． 標的検出のためのハプテンコンジュゲート
CA2806634A1 (en) * 2010-08-20 2012-02-23 Gruenenthal Gmbh Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
AU2011329763A1 (en) 2010-11-17 2013-05-09 Brigham And Women's Hospital Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
RU2652638C2 (ru) 2010-12-17 2018-04-28 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
BR112013029201B1 (pt) 2011-05-13 2022-08-09 Array Biopharma Inc Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
RU2664541C2 (ru) 2012-11-13 2018-08-20 Эррэй Биофарма Инк. Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
UA116455C2 (uk) 2012-11-13 2018-03-26 Еррей Біофарма Інк. Сполуки n-піролідинілсечовини, n'-піразолілсечовини, тіосечовини, гуанідину та ціаногуанідину як інгібітори кінази trka
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
JP6435315B2 (ja) 2013-03-15 2018-12-05 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高活性抗新生物薬及び抗増殖剤
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
RS59286B1 (sr) 2014-05-15 2019-10-31 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022135442A1 (zh) * 2020-12-22 2022-06-30 上海拓界生物医药科技有限公司 Cdk2抑制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646059A (en) * 1969-05-05 1972-02-29 Du Pont Plant growth regulatory ureidopyrazoles
US3754887A (en) * 1969-05-05 1973-08-28 Du Pont Ureidopyrazoles defoliants
WO1996014843A2 (en) 1994-11-10 1996-05-23 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
WO1998024768A1 (fr) * 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Nouveaux derives d'uree
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
EP1041982B1 (en) 1997-12-22 2011-10-19 Bayer HealthCare LLC INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

Also Published As

Publication number Publication date
ES2284518T3 (es) 2007-11-16
BR0013277A (pt) 2002-06-18
CO5200848A1 (es) 2002-09-27
EP1202734A4 (en) 2004-09-01
IL147925A0 (en) 2002-08-14
AR035557A1 (es) 2004-06-16
SK2082002A3 (en) 2002-09-10
CA2380786A1 (en) 2001-02-22
HK1049790A1 (zh) 2003-05-30
CN1379668A (zh) 2002-11-13
DE60034683D1 (de) 2007-06-14
ATE361070T1 (de) 2007-05-15
MXPA02001497A (es) 2003-07-21
NZ517238A (en) 2004-01-30
EA200200249A1 (ru) 2002-08-29
PL354058A1 (en) 2003-12-15
US6387900B1 (en) 2002-05-14
NO20020687L (no) 2002-04-03
ZA200201118B (en) 2003-05-28
KR20020060158A (ko) 2002-07-16
JP2003507328A (ja) 2003-02-25
WO2001012188A1 (en) 2001-02-22
AU6747000A (en) 2001-03-13
DE60034683T2 (de) 2008-01-17
EP1202734B1 (en) 2007-05-02
HUP0301857A2 (hu) 2003-09-29
PE20010482A1 (es) 2001-04-20
EP1202734A1 (en) 2002-05-08

Similar Documents

Publication Publication Date Title
NO20020687D0 (no) 3(5)-ureidopyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler
NO20020684L (no) 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler
NO20012058L (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20012057D0 (no) 2-amino-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20015477D0 (no) 4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler
NO963506D0 (no) 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler
DK1204649T3 (da) Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
NO20032733L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
NO20006251D0 (no) Benzotiepin-1,1-dioksidderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
NO20014013L (no) 16-halogen-epotilonderivater, fremgangsmåter for fremstilling av disse og farmasöytisk anvendelse av dem
NO20016038L (no) Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
NO990246L (no) Akryloylsubstituert distamycinderivater, fremgangsmÕte til fremstilling av disse, og deres anvendelse som antitumor- og antivirusmidler
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
NO985307D0 (no) Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvendelse som antitumor- og antivirale midler
NO20010219L (no) Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel
NO20016404D0 (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
DK1075471T3 (da) Idolylderivater som serotonerge midler
NO20002959D0 (no) Echinocandinderivater, fremgangsmÕte for fremstilling av slike og deres anvendelse som anti-soppmidler
NO20014393L (no) 1,3,4-oksadiazol-derivater og fremgangsmåte for fremstilling av disse
NO20020308D0 (no) Fremgangsmåte for fremstilling av epothiolon B og derivater, såvel som mellomprodukter for fremgangsmåten
NO20023845L (no) Pluraflaviner og derivater derav, fremgangsmåte for fremstilling av disse og deres anvendelse
DK1235809T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler
DK1124810T3 (da) 2-amino-thiazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application